VEC.L Share News (VEC)

VEC.L Information

There is currently no data for VEC

Breezhaler better than Seretide, says Vectura

Mon, 05th Sep 2016 07:42

(ShareCast News) - Inhaled airways disease focused pharmaceuticals company Vectura Group confirmed an announcement from its alliance partner Novartis on Monday, that new analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler is a "more effective option" for patients at risk of chronic obstructive pulmonary disease flare-ups than Seretide.The FTSE 250 firm said the finding was true across different patient sub-groups.In the new analyses, once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of all exacerbations, regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels and previous inhaled corticosteroid use, versus twice-daily Seretide 50/500 mcg."Specifically, among patients with the severest forms of COPD, Ultibro Breezhaler significantly reduced the rate of exacerbations and improved their health status versus the commonly used ICS/LABA combination," Vectura's board said in the statement."In addition, patients using Ultibro Breezhaler needed less rescue medication during the day."It added that new analyses presented at ERS 2016 also showed that, compared to Seretide, Ultibro Breezhaler was associated with fewer systemic effects, namely impairment of adrenal function, which regulates the natural production of hormones."Ultibro Breezhaler use has previously shown to be associated with significantly fewer cases of pneumonia than the ICS/LABA combination."Vectura said Novartis is presenting over 35 abstracts from across its broad respiratory portfolio at ERS 2016."These new findings further demonstrate the superior efficacy of Ultibro Breezhaler versus Seretide across a range of patient sub-groups and support its use as a steroid-free treatment option for COPD patients at risk of exacerbations," explained Vectura CEO James Ward-Lilley."This, combined with the existing efficacy and safety profile of Ultibro Breezhaler, further confirms our confidence in its outlook."

More News

19 Apr 2018 12:53

hVIVO CEO Steps Down In Favour Of Executive Chair As Loss Narrows

LONDON (Alliance News) - Clinical development and drug discovery business hVIVO PLC said Thursday its loss narrowed in 2017 as Chief Executive Kym Denny stepped aside for Executive Chairman Trevor

3 Apr 2018 08:41

EUROPE RESEARCH ROUNDUP-Aevis Victoria, Martela Oyj, Mediaset

April 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Aevis Victoria, Martela Oyj and Mediaset, on Tuesday. HIGHLIGHTS * Aevis SA

23 Mar 2018 18:23

DIRECTOR DEALINGS: Vectura Non-Executive Juliet Thompson Buys Shares

LONDON (Alliance News) - Vectura Group PLC said Friday Non-Executive Director Juliet Thompson bought shares worth GBP36,284 in the pharmaceutical company after

22 Mar 2018 16:16

DIRECTOR DEALINGS: Vectura Chairman, Non-Exec Director Buy Shares

LONDON (Alliance News) - Vectura Group PLC said on Thursday that two directors bought shares in the company on Wednesday.Chairman Bruno Angelici purchased 75,000 shares

21 Mar 2018 08:52

Vectura Delivers "Good" 2017 Results Despite Advair Disappointment

LONDON (Alliance News) - Pharmaceutical firm Vectura Group PLC said Wednesday it delivered a "good" set of 2017 results with underlying profit and revenue growth to

21 Mar 2018 08:31

UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 (Reuters) - British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma for

21 Mar 2018 07:47

UPDATE 1-UK Stocks-Factors to watch on March 21

March 21 (Reuters) - Britain's FTSE 100 index is seen opening up 13 points on Wednesday, according to financial bookmakers, with futures 0.26 pct higher ahead of the cash

21 Mar 2018 07:40

Drugmaker Vectura's 2017 revenue rises 17.2 pct

March 21 (Reuters) - British drugmaker Vectura reported a 17.2 percent rise in 2017 revenue on Wednesday, aided by higher demand for its asthma products Flutiform and Ultibro. The company,

20 Mar 2018 13:21

Legal & General Increases Vectura Stake To 3.7% From Below 3% (ALLISS)

LONDON (Alliance News) - Vectura Group PLC said Tuesday FTSE 100-listed insurer and asset manager Legal & General Group PLC increased its stake in the pharmaceutical firm

14 Mar 2018 16:20

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 15 March Old MutualFull Year ResultsPhoenix GroupFull Year GroupFull 16

12 Mar 2018 10:43

WINNERS & LOSERS SUMMARY: Vectura And Hikma Hurt By US FDA Ruling

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------easyJet, up 2.3% at on

12 Mar 2018 09:43

FTSE 100 lags Europe on miners and energy, Just Eat goes cold

(For a live blog on European stocks, type LIVE/ in an Eikon news window) * FTSE 100 up 0.1 pct * Just Eat hit by DB downgrade * Vectura, Hikma hit by delay to Advair GKN up 12

16 Feb 2017 07:49

Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal

16 Feb 2017 07:06

Vectura's GSK royalties agreements firing on all cylinders

(ShareCast News) - Vectura Group hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts. The cap was equivalent to £9.0m. The inhaled airways disease-focused business was also set to record £5.4m of 2016 revenues under a separate single digi

8 Feb 2017 13:49

UPDATE 1-Weak pound buoys GSK but drugmaker warns on 2017 generic threat

* 2017 core EPS seen flat-lower if mid-year generic Advair * Current exchange rates would lift 2017 sterling EPS 9 pct * Q4 2016 core EPS 26.1 pence vs consensus forecast 25.0p (Adds CEO comments, shares, background on new CEO) By Ben Hirschler LONDON, Feb 8 (Reuters) -

Latest Share Chat

VEC.L Share News (VEC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Breezhaler better than Seretide, says Vectura

Login to your account

Quickpicks are a member only feature

Login to your account